<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">31972425</PMID>
      <DateCompleted>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2020</Year>
        <Month>11</Month>
        <Day>24</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1878-1705</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>80</Volume>
            <PubDate>
              <Year>2020</Year>
              <Month>Mar</Month>
            </PubDate>
          </JournalIssue>
          <Title>International immunopharmacology</Title>
          <ISOAbbreviation>Int Immunopharmacol</ISOAbbreviation>
        </Journal>
        <ArticleTitle>The role of JAK/STAT signaling pathway and its inhibitors in diseases.</ArticleTitle>
        <Pagination>
          <StartPage>106210</StartPage>
          <MedlinePgn>106210</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.intimp.2020.106210</ELocationID>
        <ELocationID EIdType="pii" ValidYN="Y">S1567-5769(19)32417-8</ELocationID>
        <Abstract>
          <AbstractText>The JAK/STAT signaling pathway is an universally expressed intracellular signal transduction pathway and involved in many crucial biological processes, including cell proliferation, differentiation, apoptosis, and immune regulation. It provides a direct mechanism for extracellular factors-regulated gene expression. Current researches on this pathway have been focusing on the inflammatory and neoplastic diseases and related drug. The mechanism of JAK/STAT signaling is relatively simple. However, the biological consequences of the pathway are complicated due to its crosstalk with other signaling pathways. In addition, there is increasing evidence indicates that the persistent activation of JAK/STAT signaling pathway is closely related to many immune and inflammatory diseases, yet the specific mechanism remains unclear. Therefore, it is necessary to study the detailed mechanisms of JAK/STAT signaling in disease formation to provide critical reference for clinical treatments of the diseases. In this review, we focus on the structure of JAKs and STATs, the JAK/STAT signaling pathway and its negative regulators, the associated diseases, and the JAK inhibitors for the clinical therapy.</AbstractText>
          <CopyrightInformation>Copyright Â© 2020 Elsevier B.V. All rights reserved.</CopyrightInformation>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Xin</LastName>
            <ForeName>Ping</ForeName>
            <Initials>P</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Xu</LastName>
            <ForeName>Xiaoyun</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Deng</LastName>
            <ForeName>Chengjie</ForeName>
            <Initials>C</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Liu</LastName>
            <ForeName>Shuang</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Youzhi</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing 210009, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhou</LastName>
            <ForeName>Xuegang</ForeName>
            <Initials>X</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Ma</LastName>
            <ForeName>Hongxing</ForeName>
            <Initials>H</Initials>
            <AffiliationInfo>
              <Affiliation>Clinical Laboratory Department, Najing Lishui People's Hospital, Zhongda Hospital Lishui Branch, Southeast University, Najing 211200, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Wei</LastName>
            <ForeName>Donghua</ForeName>
            <Initials>D</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Sun</LastName>
            <ForeName>Shiqin</ForeName>
            <Initials>S</Initials>
            <AffiliationInfo>
              <Affiliation>College of Pharmacy, Harbin Medical University-Daqing, Daqing 163319, China. Electronic address: ssq7610@126.com.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
          <PublicationType UI="D016454">Review</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2020</Year>
          <Month>01</Month>
          <Day>20</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <Country>Netherlands</Country>
        <MedlineTA>Int Immunopharmacol</MedlineTA>
        <NlmUniqueID>100965259</NlmUniqueID>
        <ISSNLinking>1567-5769</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D016207">Cytokines</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D047428">Protein Kinase Inhibitors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D050791">STAT Transcription Factors</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.10.2</RegistryNumber>
          <NameOfSubstance UI="D053612">Janus Kinases</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007154" MajorTopicYN="N">Immune System Diseases</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName>
          <QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053612" MajorTopicYN="N">Janus Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D047428" MajorTopicYN="N">Protein Kinase Inhibitors</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
          <QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D050791" MajorTopicYN="N">STAT Transcription Factors</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
          <QualifierName UI="Q000276" MajorTopicYN="Y">immunology</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">JAK/STAT pathway and diseases</Keyword>
        <Keyword MajorTopicYN="N">JAK/STAT signaling pathway</Keyword>
        <Keyword MajorTopicYN="N">JAKs inhibitors and diseases</Keyword>
        <Keyword MajorTopicYN="N">Negative regulators</Keyword>
      </KeywordList>
      <CoiStatement>Declaration of Competing Interest The authors declare no conflict of interest.</CoiStatement>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2019</Year>
          <Month>10</Month>
          <Day>22</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="revised">
          <Year>2019</Year>
          <Month>12</Month>
          <Day>19</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="accepted">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>8</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2020</Year>
          <Month>11</Month>
          <Day>25</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2020</Year>
          <Month>1</Month>
          <Day>24</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31972425</ArticleId>
        <ArticleId IdType="doi">10.1016/j.intimp.2020.106210</ArticleId>
        <ArticleId IdType="pii">S1567-5769(19)32417-8</ArticleId>
      </ArticleIdList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
